niacinamide has been researched along with Kidney Failure in 12 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
Kidney Failure: A severe irreversible decline in the ability of kidneys to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Although clinical trials with sunitinib and sorafenib in metastatic renal cell carcinoma (mRCC) have included patients with moderate renal insufficiency (RI), the incidence of renal toxicity induced by their administration as well as the safety of these agents in patients with more severe renal insufficiency has not been extensively reported." | 7.76 | Sunitinib and sorafenib in metastatic renal cell carcinoma patients with renal insufficiency. ( Bukowski, R; Elson, P; Garcia, J; Golshayan, A; Khan, G; Rini, B; Wood, L, 2010) |
| "Although clinical trials with sunitinib and sorafenib in metastatic renal cell carcinoma (mRCC) have included patients with moderate renal insufficiency (RI), the incidence of renal toxicity induced by their administration as well as the safety of these agents in patients with more severe renal insufficiency has not been extensively reported." | 3.76 | Sunitinib and sorafenib in metastatic renal cell carcinoma patients with renal insufficiency. ( Bukowski, R; Elson, P; Garcia, J; Golshayan, A; Khan, G; Rini, B; Wood, L, 2010) |
| " This report describes the findings from 2 phase 1 studies assessing the pharmacokinetic (PK) profile of a single dose of asciminib (40 mg) in individuals with impaired renal function (based on absolute glomerular filtration rate; NCT03605277) or impaired hepatic function (based on Child-Pugh classification; NCT02857868)." | 3.01 | Pharmacokinetics of Asciminib in Individuals With Hepatic or Renal Impairment. ( Aimone, P; Allepuz, A; Hoch, M; Hourcade-Potelleret, F; Quinlan, M; Sato, M; Sengupta, T; Zack, J, 2021) |
| "Sorafenib was administered as a 400-mg dose on day 1 for PK, and continuous daily dosing started on day 8." | 2.74 | Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. ( Abou-Alfa, G; Dees, EC; Desai, A; Edelman, MJ; Fakih, MG; Frank, RC; Hohl, RJ; Hollis, DR; Hwang, J; Kennedy, EB; Lewis, LD; Millard, F; Miller, AA; Murry, DJ; Owzar, K; Ratain, MJ; Villalona-Calero, MA, 2009) |
| " Two subjects (one in the normal group and one in the mildly impaired group) each experienced a treatment-emergent adverse event (TEAE)." | 1.56 | Pharmacokinetics and Safety of a Single Oral Dose of Peficitinib (ASP015K) in Japanese Subjects with Normal and Impaired Renal Function. ( Furihata, K; Kaneko, Y; Katashima, M; Miyatake, D; Nishimura, T; Oda, K; Sekino, H; Shibata, M; Shibata, T; Urae, A, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (8.33) | 18.2507 |
| 2000's | 5 (41.67) | 29.6817 |
| 2010's | 3 (25.00) | 24.3611 |
| 2020's | 3 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Miyatake, D | 1 |
| Shibata, T | 1 |
| Shibata, M | 1 |
| Kaneko, Y | 1 |
| Oda, K | 1 |
| Nishimura, T | 1 |
| Katashima, M | 1 |
| Sekino, H | 1 |
| Furihata, K | 1 |
| Urae, A | 1 |
| Kumakura, S | 1 |
| Sato, E | 1 |
| Sekimoto, A | 1 |
| Hashizume, Y | 1 |
| Yamakage, S | 1 |
| Miyazaki, M | 1 |
| Ito, S | 1 |
| Harigae, H | 1 |
| Takahashi, N | 1 |
| Hoch, M | 1 |
| Sato, M | 1 |
| Zack, J | 1 |
| Quinlan, M | 1 |
| Sengupta, T | 1 |
| Allepuz, A | 1 |
| Aimone, P | 1 |
| Hourcade-Potelleret, F | 1 |
| Izzedine, H | 1 |
| Mangier, M | 1 |
| Ory, V | 1 |
| Zhang, SY | 1 |
| Sendeyo, K | 1 |
| Bouachi, K | 1 |
| Audard, V | 1 |
| Péchoux, C | 1 |
| Soria, JC | 1 |
| Massard, C | 1 |
| Bahleda, R | 1 |
| Bourry, E | 1 |
| Khayat, D | 1 |
| Baumelou, A | 1 |
| Lang, P | 1 |
| Ollero, M | 1 |
| Pawlak, A | 1 |
| Sahali, D | 1 |
| McKay, RR | 1 |
| Lin, X | 1 |
| Perkins, JJ | 1 |
| Heng, DY | 1 |
| Simantov, R | 1 |
| Choueiri, TK | 1 |
| Miller, AA | 1 |
| Murry, DJ | 1 |
| Owzar, K | 1 |
| Hollis, DR | 1 |
| Kennedy, EB | 1 |
| Abou-Alfa, G | 1 |
| Desai, A | 1 |
| Hwang, J | 1 |
| Villalona-Calero, MA | 1 |
| Dees, EC | 1 |
| Lewis, LD | 1 |
| Fakih, MG | 1 |
| Edelman, MJ | 1 |
| Millard, F | 1 |
| Frank, RC | 1 |
| Hohl, RJ | 1 |
| Ratain, MJ | 1 |
| Khan, G | 1 |
| Golshayan, A | 1 |
| Elson, P | 1 |
| Wood, L | 1 |
| Garcia, J | 1 |
| Bukowski, R | 1 |
| Rini, B | 1 |
| Carrey, EA | 3 |
| Smolenski, RT | 2 |
| Edbury, SM | 2 |
| Laurence, A | 2 |
| Marinaki, AM | 2 |
| Duley, JA | 2 |
| Zhu, L | 1 |
| Goldsmith, DJ | 2 |
| Simmonds, HA | 3 |
| Zhu, LM | 1 |
| Dobrovolsky, VN | 1 |
| Bowyer, JF | 1 |
| Pabarcus, MK | 1 |
| Heflich, RH | 1 |
| Williams, LD | 1 |
| Doerge, DR | 1 |
| Arvidsson, B | 1 |
| Bergquist, J | 1 |
| Casida, JE | 1 |
| Synesiou, E | 1 |
| Fairbanks, LD | 1 |
| Maïza, A | 1 |
| Daley-Yates, PT | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pharmacokinetic (PK) Study of ASP015K -Evaluation of Pharmacokinetics in Patients With Impaired Renal Function and Subjects With Normal Renal Function-[NCT02603497] | Phase 1 | 31 participants (Actual) | Interventional | 2015-11-24 | Completed | ||
| A Phase I, Open-label and Single-dose Study to Evaluate the Pharmacokinetics and Safety of a Single 40 mg Oral Dose of ABL001 (Asciminib) in Subjects With Impaired Renal Function Compared to Matched Control Subjects With Normal Renal Function[NCT03605277] | Phase 1 | 14 participants (Actual) | Interventional | 2018-11-16 | Completed | ||
| A Phase I, Open-label, Multi-center, Single-dose Study to Evaluate the Pharmacokinetics of ABL001 in Healthy Subjects With Normal Hepatic Function and Subjects With Impaired Hepatic Function[NCT02857868] | Phase 1 | 32 participants (Actual) | Interventional | 2016-05-03 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for niacinamide and Kidney Failure
| Article | Year |
|---|---|
Pharmacokinetics of Asciminib in Individuals With Hepatic or Renal Impairment.
Topics: Aged; Area Under Curve; Female; Glomerular Filtration Rate; Half-Life; Humans; Liver Failure; Male; | 2021 |
Pharmacokinetics of Asciminib in Individuals With Hepatic or Renal Impairment.
Topics: Aged; Area Under Curve; Female; Glomerular Filtration Rate; Half-Life; Humans; Liver Failure; Male; | 2021 |
Pharmacokinetics of Asciminib in Individuals With Hepatic or Renal Impairment.
Topics: Aged; Area Under Curve; Female; Glomerular Filtration Rate; Half-Life; Humans; Liver Failure; Male; | 2021 |
Pharmacokinetics of Asciminib in Individuals With Hepatic or Renal Impairment.
Topics: Aged; Area Under Curve; Female; Glomerular Filtration Rate; Half-Life; Humans; Liver Failure; Male; | 2021 |
Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Fema | 2009 |
10 other studies available for niacinamide and Kidney Failure
| Article | Year |
|---|---|
Pharmacokinetics and Safety of a Single Oral Dose of Peficitinib (ASP015K) in Japanese Subjects with Normal and Impaired Renal Function.
Topics: Adamantane; Administration, Oral; Adult; Aged; Female; Humans; Janus Kinase Inhibitors; Male; Middle | 2020 |
Nicotinamide Attenuates the Progression of Renal Failure in a Mouse Model of Adenine-Induced Chronic Kidney Disease.
Topics: Adenine; Animals; Citric Acid Cycle; Disease Models, Animal; Disease Progression; Energy Metabolism; | 2021 |
Expression patterns of RelA and c-mip are associated with different glomerular diseases following anti-VEGF therapy.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Angiogenesis Inhibitors; Animals; Base Sequence; | 2014 |
Prognostic significance of bone metastases and bisphosphonate therapy in patients with renal cell carcinoma.
Topics: Aged; Antineoplastic Agents; Axitinib; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Dens | 2014 |
Sunitinib and sorafenib in metastatic renal cell carcinoma patients with renal insufficiency.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidn | 2010 |
Origin and characteristics of an unusual pyridine nucleotide accumulating in erythrocytes: positive correlation with degree of renal failure.
Topics: Chromatography, High Pressure Liquid; Creatinine; Erythrocytes; Humans; Kidney Transplantation; Niac | 2003 |
An unusual pyridine nucleotide accumulating in erythrocytes: its identity and positive correlation with degree of renal failure.
Topics: Chromatography, High Pressure Liquid; Chromatography, Liquid; Erythrocytes; Humans; Kidney; Mass Spe | 2004 |
Effect of arylformamidase (kynurenine formamidase) gene inactivation in mice on enzymatic activity, kynurenine pathway metabolites and phenotype.
Topics: Animals; Arylformamidase; Gene Silencing; Kidney; Kynurenine; Liver; Lymphocyte Activation; Mice; Mi | 2005 |
The novel nucleotide 4KNTP, in high concentrations in erythrocytes of renal failure children: a comparison with accumulation of other putative precursors in the plasma.
Topics: Adenosine Triphosphate; Adolescent; Child; Child, Preschool; Erythrocytes; Female; Hemofiltration; H | 2006 |
Variability in the renal clearance of cephalexin in experimental renal failure.
Topics: Animals; Autoantibodies; Basement Membrane; Cephalexin; Cisplatin; Glomerular Filtration Rate; Glome | 1993 |